<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000189.pub2" GROUP_ID="MUSKEL" ID="883899092615352638" MERGED_FROM="" MODIFIED="2008-11-09 06:13:51 +0100" MODIFIED_BY="Elizabeth Tanjong Ghogomu" REVIEW_NO="C076-R" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2008-11-08 23:47:25 -0500" MODIFIED_BY="[Empty name]">
<TITLE>Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis</TITLE>
<CONTACT>
<PERSON ID="6571" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Gøtzsche</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>pcg@cochrane.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT>
<ORGANISATION>Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7112</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7007</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2008-11-08 23:40:29 -0500" MODIFIED_BY="Elizabeth Tanjong Ghogomu">
<PERSON ID="6571" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Peter</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Gøtzsche</LAST_NAME>
<SUFFIX/>
<POSITION>Director</POSITION>
<EMAIL_1>pcg@cochrane.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT>
<ORGANISATION>Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9, 3343</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 3545 7112</PHONE_1>
<PHONE_2/>
<FAX_1>+45 3545 7007</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="12436" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Helle Krogh</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Johansen</LAST_NAME>
<SUFFIX/>
<POSITION>Senior Researcher</POSITION>
<EMAIL_1>hkj@cochrane.dk</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>The Nordic Cochrane Centre</DEPARTMENT>
<ORGANISATION>Rigshospitalet, Dept. 3343</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen Ø</CITY>
<ZIP>DK-2100</ZIP>
<REGION/>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 35 45 7112</PHONE_1>
<PHONE_2/>
<FAX_1>+45 35 45 70 07</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2008-11-08 23:42:37 -0500" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="5" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="5" MONTH="11" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="2" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="" YEAR=""/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2008-11-08 23:47:25 -0500" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-11-08 23:47:25 -0500" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="11" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
<P>CMSD ID: C076-R</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-11-08 23:44:27 -0500" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>Medical Research Council</NAME>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT>
<SUMMARY>
<TITLE>Corticosteroids versus placebo and NSAIDs for rheumatoid arthritis</TITLE>
<SUMMARY_BODY>
<P>Short-term low-dose corticosteroids compared with placebo and nonsteroidal antiinflammatory drugs in patients with rheumatoid arthritis</P>
<P>Corticosteroid drugs can relieve inflammation, and in high doses they have a dramatic effect on the symptoms of rheumatoid arthritis. They are used only temporarily, however, because of serious adverse effects during long-term use. The review found that corticosteroids in low doses are very effective. They are more effective than usual anti-arthritis medications (non-steroidal anti-inflammatory drugs, or NSAIDs). The risk of harms needs to be considered, however, especially the risk of fractures and infections. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>The effect of low dose corticosteroids, equivalent to 15 mg prednisolone daily or less, in patients with rheumatoid arthritis has been questioned. We reviewed the trials that compared corticosteroids with placebo or non-steroidal, anti-inflammatory drugs.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine whether short-term (i.e. as recorded within the first month of therapy), oral low-dose corticosteroids (corresponding to a maximum of 15 mg prednisolone daily) is superior to placebo and non-steroidal, anti-inflammatory drugs in patients with rheumatoid arthritis.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>PubMed, the Cochrane Central Register of Controlled Trials, reference lists and a personal archive. Date of last search Nov 2007.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised trials comparing an oral corticosteroid (not exceeding an equivalent of 15 mg prednisolone daily) with placebo or a non-steroidal, anti-inflammatory drug were eligible if they reported clinical outcomes within one month after start of therapy. For adverse effects, long-term trials were also selected.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Decisions on which trials to include were made independently by two observers based on the methods sections of the trials. Standardised mean difference (random effects model) was used for the statistical analyses.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eleven trials, involving 462 patients, were included. Two placebo-controlled trials had adequate allocation concealment. For joint tenderness, the standardised mean difference was -0.52, 95% confidence interval (CI) -1.01 to -0.03, for pain it was -0.67, 95% CI -1.58 to 0.23, and for grip strength, 0.22, 95% CI -0.40 to 0.84. The estimates for the other trials were considerably larger. </P>
<P>Prednisolone also had a greater effect than non-steroidal, anti-inflammatory drugs on joint tenderness (-0.63, 95% CI -1.16 to -0.11) and pain (-1.25, 95% CI -2.24 to -0.26), whereas the difference in grip strength was not significant (0.31, 95% CI -0.02 to 0.64). The main harms in long-term treatment were vertebral fractures and infections. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means. The risk of harms needs to be considered, however, especially the risk of fractures and infections. Since prednisolone is highly effective, short-term placebo controlled trials studying the clinical effect of low-dose prednisolone or other oral corticosteroids are no longer necessary.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY>
<BACKGROUND>
<P>Corticosteroids were first shown to be effective in patients with rheumatoid arthritis in an uncontrolled study (<LINK REF="REF-Hench-1949" TYPE="REFERENCE">Hench 1949</LINK>). In 1959, a two-year randomised trial showed that an initial dose of prednisolone 20 mg daily was significantly superior to aspirin 6 g daily (<LINK REF="STD-Joint-Committee-1959" TYPE="STUDY">Joint Committee 1959</LINK>). Important harms were also noted, however, and the authors concluded that the highest acceptable dose for long-term therapy is probably in the region of 10 mg daily. </P>
<P>Corticosteroids have received renewed interest in recent years because of their possible beneficial effect on radiological progression (<LINK REF="REF-Weiss-1989" TYPE="REFERENCE">Weiss 1989</LINK>). Tendencies towards such an effect have been noted both in the early trials and in a more recent report (<LINK REF="STD-Kirwan-1995" TYPE="STUDY">Kirwan 1995</LINK>) and will be examined in a Cochrane review (<LINK REF="REF-Kirwan-2007" TYPE="REFERENCE">Kirwan 2007</LINK>). </P>
<P>These findings are interesting, but oral corticosteroids are still being used mainly in high doses for their symptomatic effect, for example for acute exacerbations of rheumatoid arthritis and as "bridge therapy", before slow-acting drugs have taken effect (<LINK REF="STD-Harris-1983" TYPE="STUDY">Harris 1983</LINK>). The effect of low doses has been variable, and was questioned as late as in 1995 when the most recent trial of low-dose steroids was published (<LINK REF="STD-van-Gestel-1995" TYPE="STUDY">van Gestel 1995</LINK>). We performed a systematic review of randomised trials which compared corticosteroids, given at a dose equivalent to no more than 15 mg prednisolone daily, with placebo or with non-steroidal, anti-inflammatory drugs. Our review is limited to the short-term effect, i.e. as recorded within the first month of therapy. However, in an analysis of the harms of steroids we also included long-term trials. </P>
</BACKGROUND>
<OBJECTIVES>
<P>To compare the short-term beneficial and harmful effects, i.e. as recorded within the first month of therapy, of oral low-dose corticosteroids with that of placebo and non-steroidal, anti-inflammatory drugs in patients with rheumatoid arthritis.</P>
<P>To compare the harms in long-term trials of oral low-dose corticosteroids with that of placebo and non-steroidal, anti-inflammatory drugs.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>All randomised trials comparing an oral corticosteroid with placebo or a non-steroidal, anti-inflammatory drug in patients with rheumatoid arthritis were eligible if they reported clinical outcomes within one month after start of therapy. When there were data from several visits, the data which came closest to one week of therapy was used for the analyses. We excluded studies with high-dose steroids (exceeding an equivalent of 15 mg prednisolone daily); studies of combination therapies, for instance of a steroid and a non-steroidal, anti-inflammatory drug, and studies using quasi-randomisation methods, such as allocation by date of admission or by toss of a coin (no such studies were found). </P>
<P>To study the harms in more detail, we also identified moderate- and long-term randomised trials, which had compared low-dose steroids with placebo or a non-steroidal, anti-inflammatory drug.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Patients with rheumatoid arthritis, in all but one study defined by the criteria of the American Rheumatism Association (<LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>) (the criteria have changed slightly over the years).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Experimental: oral low-dose corticosteroids (not exceeding an equivalent of 15 mg prednisolone daily). <BR/>Control: placebo or oral non-steroidal, anti-inflammatory drugs.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES>
<P>Joint tenderness (usually Ritchie's joint index), pain, grip strength.</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS>
<P>PubMed was searched from 1966 to November 2007: "Arthritis, Rheumatoid"[mh] AND placebo AND "Glucocorticoids"[Pharmacological Action].<BR/>The Cochrane Central Register of Controlled Trials was searched in November 2007: (glucocorticoids explode all trees (MeSH) and (Arthritis, Rheumatoid explode all trees (MeSH)) and placebo. The reference lists were scanned for additional trials and an archive in possession of one of the authors was scanned. Since most of the retrieved trials were very old and the steroid drugs were non-proprietary ones, authors and companies were not asked about possible unpublished studies. </P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Decisions on which trials to include were taken independently by two observers based on the methods sections of the trials; disagreements were resolved by discussion. Details on the nature and dosage of treatments, number of randomised patients, the randomisation and blinding procedures, and exclusions after randomisation were noted. Since the outcomes were measured on different scales, even when they referred to the same quality, e.g. tender joints, we calculated the standardised mean difference. With this method, the difference in effect between two treatments is divided by the standard deviation of the measurements. By that transformation, the effect measures become dimension-less and outcomes from trials which have used different scales may therefore often be combined. As an example, the tender joint count may be recorded either as the number of tender joints or as Ritchie's index in which each joint is scored on a scale from zero to three for pain on firm palpation, and the scores are added. If the patients have very severe disease, Ritchie's index may be higher, but the standard deviation will then also be higher, and by dividing the counts with their standard deviations, the effect sizes will be of the same magnitude.</P>
<P>The random effects model was used since there was substantial heterogeneity. As the trials were all small, this would not be expected to lead to overestimation of treatment effects. Since data from crossover trials were only reported in summary form, as if they had been generated from a group comparative trial, we analysed them accordingly. We therefore assumed that no important carry-over effects had occurred.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Thirty-five randomised trials were initially identified, several of which had been published more than once. Twenty-four trials were excluded for various reasons. Eleven trials did not fulfil the inclusion criteria for the meta-analysis: one was not randomised although so labelled in PubMed (<LINK REF="STD-Hantzschel-1976" TYPE="STUDY">Hantzschel 1976</LINK>), five had studied combination drugs (<LINK REF="STD-Badia-Flores-1969" TYPE="STUDY">Badia Flores 1969</LINK>; <LINK REF="STD-Gum-1966" TYPE="STUDY">Gum 1966</LINK>; <LINK REF="STD-Jick-1965" TYPE="STUDY">Jick 1965</LINK>; <LINK REF="STD-Siegmeth-1974" TYPE="STUDY">Siegmeth 1974</LINK>; <LINK REF="STD-Zuckner-1969" TYPE="STUDY">Zuckner 1969</LINK>), three used too high dose (<LINK REF="STD-Hansen-1999" TYPE="STUDY">Hansen 1999</LINK>; <LINK REF="STD-Joint-Committee-1954" TYPE="STUDY">Joint Committee 1954</LINK>; <LINK REF="STD-Joint-Committee-1959" TYPE="STUDY">Joint Committee 1959</LINK>), in one, 4 mg methylprednisolone was given to all the patients in the placebo group (<LINK REF="STD-Slonim-1969" TYPE="STUDY">Slonim 1969</LINK>), and one concerned patients with juvenile rheumatoid arthritis (<LINK REF="STD-Kvien-1982" TYPE="STUDY">Kvien 1982</LINK>) (this trial found prednisolone to be significantly better than placebo). The other 15 excluded studies were potentially eligible for the review. However, one was a five-way crossover trial (<LINK REF="STD-Deodhar-1973" TYPE="STUDY">Deodhar 1973</LINK>) with a grossly unbalanced design; for instance, placebo was given to 9, 13, 3, 6, and 6 patients during weeks 1, 2, 3, 4, and 5, respectively. Because of the regression towards the mean effect, we found it inappropriate to include this trial. Another trial was also unbalanced, since the steroid group was kept mobile whereas the control group received bed rest and splints for the inflamed joints (<LINK REF="STD-Million-1984" TYPE="STUDY">Million 1984</LINK>). Two trials were too poorly reported to be usable (<LINK REF="STD-Fearnley-1966" TYPE="STUDY">Fearnley 1966</LINK>; <LINK REF="STD-Murthy-1978" TYPE="STUDY">Murthy 1978</LINK>), and one only reported on joint size (<LINK REF="STD-Webb-1973" TYPE="STUDY">Webb 1973</LINK>). Three of these trials found prednisolone or prednisone to be significantly more effective than placebo, and one compared prednisolone and indomethacin and gave no numerical data but just reported that there was "no significant difference in response" (<LINK REF="STD-Murthy-1978" TYPE="STUDY">Murthy 1978</LINK>). The eight other excluded trials were long-term studies that did not report short-term data as well (<LINK REF="STD-Capell-2004" TYPE="STUDY">Capell 2004</LINK>; <LINK REF="STD-Chamberlain-1976" TYPE="STUDY">Chamberlain 1976</LINK>; <LINK REF="STD-Empire-Rheum-1955" TYPE="STUDY">Empire Rheum 1955</LINK>; <LINK REF="STD-van-Everdingen-2002" TYPE="STUDY">van Everdingen 2002</LINK>; <LINK REF="STD-Harris-1983" TYPE="STUDY">Harris 1983</LINK>; <LINK REF="STD-Kirwan-1995" TYPE="STUDY">Kirwan 1995</LINK>; <LINK REF="STD-Leszczynski-2000" TYPE="STUDY">Leszczynski 2000</LINK>; <LINK REF="STD-Rau-2000" TYPE="STUDY">Rau 2000</LINK>). <BR/> <BR/>Eleven trials, involving 462 patients, were included in the review. Most of the trials were quite old and rather small. In all but one (<LINK REF="STD-B_x00f6_hm-1967" TYPE="STUDY">Böhm 1967</LINK>), the criteria of the American Rheumatism Association for classical or definite rheumatoid arthritis (<LINK REF="REF-Arnett-1988" TYPE="REFERENCE">Arnett 1988</LINK>) were fulfilled. Age, proportion of females and disease duration were only reported in about half of the trials but they were typical for studies in rheumatoid arthritis. As would be expected for patients becoming enrolled in steroid trials, the severity of the disease, expressed as number of tender joints or Ritchie's tender joint index, was quite pronounced (see graphs). Prednisolone was used in seven trials and prednisone in four. Since prednisone is equipotent with prednisolone and is a pro-drug to prednisolone, we will refer to "prednisolone" as a general term in the following. The doses were 2.5-7.5 mg in four studies, 10 mg in three studies, and 15 mg in four. Data were available after one week for all studies but two for which two-week and four-week data (as two-week data were difficult to read on the graphs (<LINK REF="STD-Kirwan-2004" TYPE="STUDY">Kirwan 2004</LINK>)) were used, respectively.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>The randomisation method was only described in one of the trial reports (<LINK REF="STD-Kirwan-2004" TYPE="STUDY">Kirwan 2004</LINK>) but details were obtained from the authors of another study (<LINK REF="STD-van-Gestel-1995" TYPE="STUDY">van Gestel 1995</LINK>); the treatment allocation appeared to have been adequately concealed in these two studies. All studies were double-blind apart from a single-blind study in which the patients appeared to have been blinded (<LINK REF="STD-Lee-1973b" TYPE="STUDY">Lee 1973b</LINK>). Eight of the studies were of a crossover design but only one of them reported to have tested for sequence effects (<LINK REF="STD-Stenberg-1992" TYPE="STUDY">Stenberg 1992</LINK>). Apart from one study (<LINK REF="STD-Stenberg-1992" TYPE="STUDY">Stenberg 1992</LINK>), the tender joint count was recorded as Ritchie's index; pain was recorded on a ranking scale with 4 or 5 classes in two studies (<LINK REF="STD-B_x00f6_hm-1967" TYPE="STUDY">Böhm 1967</LINK>; <LINK REF="STD-Lee-1973b" TYPE="STUDY">Lee 1973b</LINK>), on a visual analogue scale in three studies (<LINK REF="STD-Berry-1974" TYPE="STUDY">Berry 1974</LINK>; <LINK REF="STD-Kirwan-2004" TYPE="STUDY">Kirwan 2004</LINK>; <LINK REF="STD-van-Gestel-1995" TYPE="STUDY">van Gestel 1995</LINK>), and as a composite pain index in two studies (<LINK REF="STD-Jasani-1968" TYPE="STUDY">Jasani 1968</LINK>; <LINK REF="STD-Stenberg-1992" TYPE="STUDY">Stenberg 1992</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>Eleven trials, involving 462 patients were included. The results are shown in the graphs. It should be noted that if prednisolone is better than control, the standardised mean difference is negative for joint tenderness and pain, but positive for grip strength. There was large heterogeneity in the effects, and the results should therefore be interpreted with caution.</P>
<P>Two placebo-controlled trials had adequate allocation concealment. For joint tenderness, the standardised mean difference was -0.52, 95% confidence interval (CI) -1.01 to -0.03, for pain it was -0.67, 95% CI -1.58 to 0.23, and for grip strength, 0.22, -95% CI 0.40 to 0.84. The estimates for the other trials were considerably larger. </P>
<P>Prednisolone also had a greater effect than non-steroidal, anti-inflammatory drugs on joint tenderness (-0.63, 95% CI -1.16 to -0.11) and pain (-1.25, 95% CI -2.24 to -0.26), whereas the difference in grip strength was not significant (0.31, 95% CI -0.02 to 0.64). </P>
<P>The harms were poorly described. Five of the eleven studies we included for efficacy analyses did not report any data on harms; one study reported that no side effects occurred (<LINK REF="STD-Jasani-1968" TYPE="STUDY">Jasani 1968</LINK>); two patients on prednisone had "subjective reactions" in one study (<LINK REF="STD-Boardman-1967" TYPE="STUDY">Boardman 1967</LINK>); and one patient developed acute psychosis while on prednisone in one study (<LINK REF="STD-Lee-1973b" TYPE="STUDY">Lee 1973b</LINK>). The three remaining studies were moderate-term studies from which we extracted short-term efficacy data (<LINK REF="STD-Kirwan-2004" TYPE="STUDY">Kirwan 2004</LINK>; <LINK REF="STD-Stenberg-1992" TYPE="STUDY">Stenberg 1992</LINK>; <LINK REF="STD-van-Gestel-1995" TYPE="STUDY">van Gestel 1995</LINK>) and moderate- term adverse effects.</P>
<P>We found 12 moderate- and long-term randomised trials which had compared low-dose steroids with placebo or a non-steroidal, anti-inflammatory drug (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>). Because of differences in evaluation of harms and in reporting them, we did not try to pool these data. In five of the trials (203 vs 202 patients), where X-ray had been used to detect vertebral fractures, nine fractures on corticosteroids and four on placebo were reported. The incidence of infections was also increased with corticosteroids (for other reported harms, see <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).<BR/> </P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>Low-dose prednisolone is not only highly effective for short-term therapy, but also significantly more effective than non-steroidal, anti-inflammatory drugs. A systematic review of the effect of low-dose prednisolone after six months also found a significantly better effect of drug than of placebo (<LINK REF="REF-Criswell-1998" TYPE="REFERENCE">Criswell 1998</LINK>). </P>
<P>The point estimate for the difference in effect between prednisolone and non-steroidal, anti-inflammatory drugs on grip strength was 12 mm Hg, which is the same as the point estimate for the difference in effect between non-steroidal, anti-inflammatory drugs and placebo (<LINK REF="REF-G_x00f8_tzsche-1989b" TYPE="REFERENCE">Gøtzsche 1989b</LINK>). It is not surprising that the difference in grip strength between prednisolone and non-steroidal, anti-inflammatory drugs was not statistically significant, since this effect measure is considerably less sensitive to drug effects than pain and joint tenderness (<LINK REF="REF-G_x00f8_tzsche-1990a" TYPE="REFERENCE">Gøtzsche 1990a</LINK>). </P>
<P>There was substantial heterogeneity between the trials. Our attempts to explain its causes have been rather unsuccessful. Since most of the studies were performed decades ago, earlier trials could have overestimated the effect, for instance because of insufficiently concealed randomisation methods (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>). However, the methodological quality of the trials was rather similar in the whole time span of 40 years and it was also similar to the quality of comparative drug trials of non-steroidal, anti-inflammatory (<LINK REF="REF-G_x00f8_tzsche-1989a" TYPE="REFERENCE">Gøtzsche 1989a</LINK>). In accordance with this, there were no time trends for the differences in joint tenderness and pain between prednisolone and placebo (see graphs). Blinding did not seem to have been important for the heterogeneity. Only one trial was not double-blind and this trial did not yield larger effect estimates than the other trials.</P>
<P>Small trials may exaggerate the effect because of publication bias (<LINK REF="REF-Dickersin-1993" TYPE="REFERENCE">Dickersin 1993</LINK>; <LINK REF="REF-Stern-1997" TYPE="REFERENCE">Stern 1997</LINK>) and other biases. The trials were all rather small, but the effect was so pronounced that it would have been unreasonable to plan large, confirmatory trials. In this respect , steroid trials resemble trials of non-steroidal, anti-inflammatory drugs which have been shown to be effective in small crossover trials against placebo (<LINK REF="REF-G_x00f8_tzsche-1990a" TYPE="REFERENCE">Gøtzsche 1990a</LINK>). </P>
<P>A possible cause for the heterogeneity could be varying degrees of concomitant therapy. Although sometimes prohibited in trial protocols, it may be difficult to ensure that patients do not take additional drugs. Since there was very sparse information on drug intake in the reports, this possibility could not be evaluated.</P>
<P>Another source of heterogeneity could be the use of different measurement scales. Pain, for example, was measured on three different types of scales. They were all ranking scales, and we would therefore have preferred to analyse pain with rank sum tests, or as binary data after reduction of the level of measurement. Since the original authors had used parametric statistics, we decided to do so as well, rather than discard the data. </P>
<P>There was no clear relation between dose and effect despite the fact that the doses varied from 2.5 mg to 15 mg daily. It was not the aim of our review, however, to study dose-response relationships which are elucidated more reliably in studies where patients are randomised to different doses. A remarkable effect was seen in a study in which the average dose was only 3 mg daily but where the patients were allowed to start on 7.5 mg when they experienced flares of the arthritis and were advised to take nothing when they were well (<LINK REF="STD-Stenberg-1992" TYPE="STUDY">Stenberg 1992</LINK>). This study suggests that it could be an advantage to take steroids intermittently which would also diminish their harms.</P>
<P>It could be discussed whether we were too liberal by including crossover trials for which we assumed that no important carryover effects had occurred. We believe our approach is justified since one would not expect carryover problems for drugs with relatively quick and reversible symptomatic effects such as steroids or non-steroidal, anti-inflammatory drugs in patients with rheumatoid arthritis. In fact, in a meta-analysis of non-steroidal, anti-inflammatory drugs, very similar results were obtained with the two trial designs (<LINK REF="REF-G_x00f8_tzsche-1989b" TYPE="REFERENCE">Gøtzsche 1989b</LINK>). Only three studies were of a group comparative design, and the heterogeneity we found could not be explained by type of design. </P>
<P>The titles of the included trials were generally quite uninformative and some of them would not have been too easy to find since they were performed within experiments designed to study other factors. Several of the studies were retrieved from an archive in possession of one of the authors, assembled during work on a thesis (<LINK REF="REF-G_x00f8_tzsche-1990b" TYPE="REFERENCE">Gøtzsche 1990b</LINK>), before the electronic data searches were performed. The authors of a long-term study (<LINK REF="STD-van-Gestel-1995" TYPE="STUDY">van Gestel 1995</LINK>) had only found one of five trials comparing steroids with placebo in long-term studies, and none of the nine short-term trials included in our review. These short-term trials were described in eleven reports which were all indexed in PubMed with the term for rheumatoid arthritis; in addition, all but one (<LINK REF="STD-Jasani-1968" TYPE="STUDY">Jasani 1968</LINK>) contained the terms for clinical trial or comparative study. Further, all nine trials were identifiable by using the search term placebo* and (prednisone or prednisolone). This illustrates the value of a systematic and careful search of the literature before starting new clinical trials. To diminish the risk of unnecessary research, funding bodies and ethical review committees should demand a systematic review of the relevant literature before approving of new clinical research (<LINK REF="REF-Savulescu-1996" TYPE="REFERENCE">Savulescu 1996</LINK>).</P>
<P>We found two studies of matched cohorts that described the harms of corticosteroids (<LINK REF="REF-McDougall-1994" TYPE="REFERENCE">McDougall 1994</LINK>; <LINK REF="REF-Saag-1994" TYPE="REFERENCE">Saag 1994</LINK>). One of the matched cohort studies had included 112 patients who had received 15 mg prednisolone or less for at least 12 months and 112 matched controls (<LINK REF="REF-Saag-1994" TYPE="REFERENCE">Saag 1994</LINK>). It used a survival type analysis and found a large difference in time to first adverse event, with a total of 92 events in the steroid group and 31 in the untreated group. The risk of fracture increased with increasing doses: odds ratio 32.3 (95% confidence interval 4.6 to 220) for &gt;10-15 mg prednisolone daily, 4.5 (95% CI 2.1 to 9.6) for 5-10 mg, and 1.9 (95% CI 0.8 to 4.7) for less than 5 mg daily. The overall risks for first event were: fracture 3.9 (95% CI 0.8 to 18.1), infection 8.0 (95% CI 1.0 to 64.0), gastrointestinal bleed or ulcer 3.3 (95% CI 0.9 to 12.1). This study also included patients who received oral steroid "pulses", which do not necessarily lead to the same incidence and severity of adverse effects as continuous low-dose treatment. The other cohort study followed two groups of 122 patients for 10 years (<LINK REF="REF-McDougall-1994" TYPE="REFERENCE">McDougall 1994</LINK>). Fractures were noted in 31 vs 19 patients, osteonecrosis in 5 vs 2, and cataracts in 36 vs 22.</P>
<P>The main problem with such studies are that the two groups can never be completely comparable, since patients treated with steroids must be expected to be more severely affected than those not treated. This fact may escape notice by traditional measures of morbidity, or the difference may be statistically significantly for one (<LINK REF="REF-McDougall-1994" TYPE="REFERENCE">McDougall 1994</LINK>) or more (<LINK REF="REF-Saag-1994" TYPE="REFERENCE">Saag 1994</LINK>) indicators of disease severity, as in the two cohort studies we reviewed. It is noteworthy, for example, that the first study (<LINK REF="REF-Saag-1994" TYPE="REFERENCE">Saag 1994</LINK>) found a similarly increased risk for fractures as for ulcers, since five meta-analyses of around one hundred randomised trials of steroids in a variety of diseases have shown either no increase in risk, or, at most, a marginally increased risk of ulcers, which lacks clinical significance (<LINK REF="REF-G_x00f8_tzsche-1994" TYPE="REFERENCE">Gøtzsche 1994</LINK>). Another meta-analysis of 71 randomised trials, which looked at the risk of infectious complications, showed no increase in risk in patients given less than 10 mg prednisolone daily, and the relative risk for a mean dose less than 20 mg was only 1.3 (95% CI 1.0 to 1.6) (<LINK REF="REF-Stuck-1989" TYPE="REFERENCE">Stuck 1989</LINK>), which is in contrast to the 8-fold increased risk in the cohort study (<LINK REF="REF-Saag-1994" TYPE="REFERENCE">Saag 1994</LINK>). Although the confidence intervals were wide in the cohort study, this illustrates the well-known dangers of non-randomised comparisons.</P>
<P>All treatments for rheumatoid arthritis, including non-steroidal, anti-inflammatory drugs and slow-acting antirheumatic drugs, may cause important harms that may occasionally be life-threatening. We therefore suggest that short-term prednisolone in low doses, i.e. not exceeding 15 mg daily, may be used intermittently in patients with rheumatoid arthritis, particularly if they have flares in their disease which cannot be controlled by other means. This suggestion is in accordance with detailed reviews of the harms of low-dose steroids (<LINK REF="REF-Caldwell-1991" TYPE="REFERENCE">Caldwell 1991</LINK>; <LINK REF="REF-Da-Silva-2006" TYPE="REFERENCE">Da Silva 2006</LINK>). Since prednisolone is highly effective, short-term placebo controlled trials studying the clinical effect of low-dose prednisolone or other oral corticosteroids are no longer necessary.</P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>Prednisolone in low doses (not exceeding 15 mg daily) may be used intermittently in patients with rheumatoid arthritis, particularly if the disease cannot be controlled by other means. The risk of harms needs to be considered, however, especially the risk of fractures and infections. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Since prednisolone is highly effective, short-term placebo controlled trials studying the clinical effect of low-dose prednisolone or other oral corticosteroids are no longer necessary.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful for the unpublished data provided by Anke van Gestel and Roland Laan.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>PCG wrote the draft protocol and manuscript. HKJ commented on the drafts. Both authors contributed to selection of studies and extraction of data. PCG is guarantor for the study</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-11-09 00:09:18 -0500" MODIFIED_BY="[Empty name]">
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Berry-1974" NAME="Berry 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Berry H, Huskisson EC. Isotopic indices as a measure of inflammation in rheumatoid arthritis. Ann Rheum Dis 1974; 33:523-5&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Berry H, Huskisson EC</AU>
<TI>Isotopic indices as a measure of inflammation in rheumatoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1974</YR>
<VL>33</VL>
<PG>523-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Boardman-1967" NAME="Boardman 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;Boardman PL, Dudley Hart F. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. BMJ 1967; 4:264-8&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Boardman PL, Dudley Hart F</AU>
<TI>Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>1967</YR>
<VL>4</VL>
<PG>264-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-B_x00f6_hm-1967" NAME="Böhm 1967" YEAR="1967">
<REFERENCE NOTES="&lt;p&gt;B&amp;#246;hm C. Zur medikament&amp;#246;sen Langzeittherapie der prim&amp;#228;r chronischen Polyarthritis. Med Welt 1967; 35:2047-50&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Böhm C</AU>
<TI>Zur medikamentösen Langzeittherapie der primär chronischen Polyarthritis</TI>
<SO>Med Welt</SO>
<YR>1967</YR>
<VL>35</VL>
<PG>2047-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Schoger GA. Zur beurteilung der Wirkung einer Kombination von Salicylaten und Prednisolon bei rheumatischen Erkrankungen. Arzneimittel-Forschung 1968; 18:758-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoger GA</AU>
<TI>Zur beurteilung der Wirkung einer Kombination von Salicylaten und Prednisolon bei rheumatischen Erkrankungen</TI>
<SO>Arzneimittel-Forschung</SO>
<YR>1968</YR>
<VL>18</VL>
<PG>758-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dick-1970" NAME="Dick 1970" YEAR="1970">
<REFERENCE NOTES="&lt;p&gt;Dick WC, Nuki G, Whaley K, Deodhar S, Buchanan WW. Some aspects in the quantitation of inflammation in joints of patients suffering from rheumatoid arthritis. Rheumatol Phys Med 1970; suppl 10:40-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dick WC, Nuki G, Whaley K, Deodhar S, Buchanan WW</AU>
<TI>Some aspects in the quantitation of inflammation in joints of patients suffering from rheumatoid arthritis</TI>
<SO>Rheumatol Phys Med</SO>
<YR>1970</YR>
<VL>suppl 10</VL>
<PG>40-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jasani-1968" NAME="Jasani 1968" YEAR="1968">
<REFERENCE NOTES="&lt;p&gt;Jasani MK, Downie WW, Samuels BM, Buchanan WW. Ibuprofen in rheumatoid arthritis. Ann Rheum Dis 1968; 27:457-62&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jasani MK, Downie WW, Samuels BM, Buchanan WW</AU>
<TI>Ibuprofen in rheumatoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1968</YR>
<VL>27</VL>
<PG>457-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirwan-2004" NAME="Kirwan 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Kirwan JR, Hallgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al. A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis. Ann Rheum Dis 2004; 63(6):688-95.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirwan JR, Hallgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al</AU>
<TI>A randomised placebo controlled 12 week trial of budesonide and prednisolone in rheumatoid arthritis</TI>
<SO>Annals of Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>6</NO>
<PG>688-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, et al. The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54(5):1415-21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirwan JR, Hickey SH, Hallgren R, Mielants H, Bjorck E, Persson T, et al</AU>
<TI>The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis</TI>
<SO>Arthritis Rheum</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>5</NO>
<PG>1415-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1973a" NAME="Lee 1973a" YEAR="1973a">
<REFERENCE NOTES="&lt;p&gt;Lee P, Jasani MK, Dick WC, uchanan W. Evaluation of a functional index in rheumatoid arthritis. Scand J Rheumatol 1973; 2:71-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee P, Jasani MK, Dick WC, uchanan W</AU>
<TI>Evaluation of a functional index in rheumatoid arthritis</TI>
<SO>Scand J Rheumatol</SO>
<YR>1973</YR>
<VL>2</VL>
<PG>71-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1973b" NAME="Lee 1973b" YEAR="1973b">
<REFERENCE NOTES="&lt;p&gt;Lee P, Anderson JA, Miller J, Webb J, Buchanan WW. Evaluation of analgesic action and efficacy of antirheumatic drugs. J Rheumatol 1976; 3:283-94.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee P, Anderson JA, Miller J, Webb J, Buchanan WW</AU>
<TI>Evaluation of analgesic action and efficacy of antirheumatic drugs</TI>
<SO>J Rheumatol</SO>
<YR>1976</YR>
<VL>3</VL>
<PG>283-94</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Lee P, Webb J, Anderson J, Buchanan WW. Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis. BMJ 1973; 2:685-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee P, Webb J, Anderson J, Buchanan WW</AU>
<TI>Method for assessing therapeutic potential of anti-inflammatory antirheumatic drugs in rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>1973</YR>
<VL>2</VL>
<PG>685-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1974" NAME="Lee 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Lee P, Baxter A, Carson Dick W, Webb J. An assessment of grip strength measurement in rheumatoid arthritis. Scand J Rheumatol 1974; 3:17-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee P, Baxter A, Carson Dick W, Webb J</AU>
<TI>An assessment of grip strength measurement in rheumatoid arthritis</TI>
<SO>Scand J Rheumatol</SO>
<YR>1974</YR>
<VL>3</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stenberg-1992" NAME="Stenberg 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Stenberg VI, Fiechtner JJ, Rice JR, Miller DR, Johnson LK. Endocrine control of inflammation: rheumatoid arthritis. Double-blind, crossover clinical trial. Int J Clin Pharm Res 1992; 12:11-18.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stenberg VI, Fiechtner JJ, Rice JR, Miller DR, Johnson LK</AU>
<TI>Endocrine control of inflammation: rheumatoid arthritis. Double-blind, crossover clinical trial</TI>
<SO>Int J Clin Pharm Res</SO>
<YR>1992</YR>
<VL>12</VL>
<PG>11-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-Gestel-1995" NAME="van Gestel 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Gestel AM van, Laan RFJM, Haagsma CJ, Putte LBA van de, Riel PLCM van. Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial. Br J Rheumatol 1995; 34:347-51.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gestel AM van, Laan RFJM, Haagsma CJ, Putte LBA van de, Riel PLCM van</AU>
<TI>Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial</TI>
<SO>Br J Rheumatol</SO>
<YR>1995</YR>
<VL>34</VL>
<PG>347-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Laan RFJM, Riel PLCM van, Putte LBA van de, Erning LJTO van, Hof MA van't, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993; 119:963-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laan RFJM, Riel PLCM van, Putte LBA van de, Erning LJTO van, Hof MA van't, Lemmens JAM</AU>
<TI>Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis</TI>
<SO>Ann Intern Med</SO>
<YR>1993</YR>
<VL>119</VL>
<PG>963-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Badia-Flores-1969" NAME="Badia Flores 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Badia Flores J. Valoracion del GP-40705 en la artritis reumatoide. Prensa Med Mex 1969; 34,9:382-4.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Badia Flores J</AU>
<TI>Valoracion del GP-40705 en la artritis reumatoide</TI>
<SO>Prensa Med Mex</SO>
<YR>1969</YR>
<VL>34,9</VL>
<PG>382-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Capell-2004" NAME="Capell 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004; 63(7):797-803.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al</AU>
<TI>Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>7</NO>
<PG>797-803</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chamberlain-1976" NAME="Chamberlain 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Chamberlain MA, Keenan J. The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis. Rheumatol Rehabil 1976; 15:17-23.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chamberlain MA, Keenan J</AU>
<TI>The effect of low doses of prednisolone compared with placebo on function and on the hypothalamic pituitary adrenal axis in patients with rheumatoid arthritis</TI>
<SO>Rheumatol Rehabil</SO>
<YR>1976</YR>
<VL>15</VL>
<PG>17-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deodhar-1973" NAME="Deodhar 1973" YEAR="1973">
<REFERENCE NOTES="&lt;p&gt;Deodhar SD, Dick WC, Hodgkinson R, Buchanan WW. Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis. Quarterly J Med 1973; 166:387-401.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deodhar SD, Dick WC, Hodgkinson R, Buchanan WW</AU>
<TI>Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis</TI>
<SO>Quarterly J Med</SO>
<YR>1973</YR>
<VL>166</VL>
<PG>387-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Empire-Rheum-1955" NAME="Empire Rheum 1955" YEAR="1955">
<REFERENCE NOTES="&lt;p&gt;Empire Rheumatism Council. Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumaoid arthritis. Ann Rheum Dis 1955; 14:353-63.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Empire Rheumatism Council</AU>
<TI>Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumaoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1955</YR>
<VL>14</VL>
<PG>353-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Empire Rheumatism Council</AU>
<TI>Multi-centre controlled trial comparing cortisone acetate and acetyl salicylic acid in the long-term treatment of rheumatoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1957</YR>
<VL>16</VL>
<PG>277-89</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fearnley-1966" NAME="Fearnley 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Fearnley ME, Masheter HC. A controlled trial of flufenamic acid therapy in rheumatoid arthritis. Ann Phys Med 1966; 8:204-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fearnley ME, Masheter HC</AU>
<TI>A controlled trial of flufenamic acid therapy in rheumatoid arthritis</TI>
<SO>Ann Phys Med</SO>
<YR>1966</YR>
<VL>8</VL>
<PG>204-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fearnly ME</AU>
<TI>An investigation of possible synergism between flufenamic acid and prednisone</TI>
<SO>Ann Phys Med</SO>
<YR>1966</YR>
<VL>suppl</VL>
<PG>109-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gum-1966" NAME="Gum 1966" YEAR="1966">
<REFERENCE NOTES="&lt;p&gt;Gum OB. A controlled study of two preparations, paramethasone, propoxyphene, and aspirin and propoxyphene and aspirin in the treatment of arthritis. Am J Med Sci 1966; 251:328-32.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gum OB</AU>
<TI>A controlled study of two preparations, paramethasone, propoxyphene, and aspirin and propoxyphene and aspirin in the treatment of arthritis</TI>
<SO>Am J Med Sci</SO>
<YR>1966</YR>
<VL>251</VL>
<PG>328-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hansen-1999" NAME="Hansen 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E et al. A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects. Ann-Rheum-Dis 1999; 58(11):713-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E et al</AU>
<TI>A randomised trial of differentiated prednisolone treatment in active rheumatoid arthritis. Clinical benefits and skeletal side effects</TI>
<SO>Ann Rheum Dis</SO>
<YR>1999</YR>
<VL>58</VL>
<NO>11</NO>
<PG>713-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hantzschel-1976" NAME="Hantzschel 1976" YEAR="1976">
<REFERENCE NOTES="&lt;p&gt;Hantzschel-H, Otto-W, Astapenko-MG, Tautenhahn-B, Trofimowa-TM, Fischer-H et al. [Results of different long term treatments of patients in the early stages of rheumatoid arthritis]. Z-Gesamte-Inn-Med 1976; 31:934-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hantzschel H, Otto W, Astapenko MG, Tautenhahn B, Trofimowa TM, Fischer H et al</AU>
<TI>[Results of different long term treatments of patients in the early stages of rheumatoid arthritis]</TI>
<SO>Z Gesamte Inn Med</SO>
<YR>1976</YR>
<VL>31</VL>
<PG>934-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Harris-1983" NAME="Harris 1983" YEAR="1983">
<REFERENCE NOTES="&lt;p&gt;Harris ED, Emkey RD, Nicols JE, Newberg A. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol 1983; 10:713-21.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Harris ED, Emkey RD, Nicols JE, Newberg A</AU>
<TI>Low dose prednisone therapy in rheumatoid arthritis: a double blind study</TI>
<SO>J Rheumatol</SO>
<YR>1983</YR>
<VL>10</VL>
<PG>713-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jick-1965" NAME="Jick 1965" YEAR="1965">
<REFERENCE NOTES="&lt;p&gt;Jick H, Pinals RS, Ullian R, Slone D, Muench H. Dexamethasone and dexamethasone-aspirin in the treatment of chronic rheumatoid arthritis. Lancet 1965; 2:1203-5.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jick H, Pinals RS, Ullian R, Slone D, Muench H</AU>
<TI>Dexamethasone and dexamethasone-aspirin in the treatment of chronic rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1965</YR>
<VL>2</VL>
<PG>1203-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Jick H, Slone D, Dinan B, Muench H. Evaluation of drug efficacy by a preference technic. N Engl J Med 1966; 275:1399-1403.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jick H, Slone D, Dinan B, Muench H</AU>
<TI>Evaluation of drug efficacy by a preference technic</TI>
<SO>N Engl J Med</SO>
<YR>1966</YR>
<VL>275</VL>
<PG>1399-1403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joint-Committee-1954" NAME="Joint Committee 1954" YEAR="1954">
<REFERENCE NOTES="&lt;p&gt;Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. BMJ 1954; 1:1223-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joint Committee of the Medical Research Council and Nuffield Foundation</AU>
<TI>A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>1954</YR>
<VL>1</VL>
<PG>1223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis. BMJ 1955; 2:695-700.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joint Committee of the Medical Research Council and Nuffield Foundation</AU>
<TI>A comparison of cortisone and aspirin in the treatment of early cases of rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>1955</YR>
<VL>2</VL>
<PG>695-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Joint Committee of the Medical Research Council and Nuffield Foundation. Long-term results in early cases of rheumatoid arthritis treated with either cortisone or aspirin BMJ 1957; 1:847-50.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joint Committee of the Medical Research Council and Nuffield Foundation</AU>
<TI>Long-term results in early cases of rheumatoid arthritis treated with either cortisone or aspirin</TI>
<SO>BMJ</SO>
<YR>1957</YR>
<VL>1</VL>
<PG>847-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joint-Committee-1959" NAME="Joint Committee 1959" YEAR="1959">
<REFERENCE NOTES="&lt;p&gt;Joint Committee of the Medical Research Council and Nuffield Foundation. A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1959; 18:173-88.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joint Committee of the Medical Research Council and Nuffield Foundation</AU>
<TI>A comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1959</YR>
<VL>18</VL>
<PG>173-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Joint Committee of the Medical Research Council and Nuffield Foundation. Comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis. Ann Rheum Dis 1960; 19:331-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joint Committee of the Medical Research Council and Nuffield Foundation</AU>
<TI>Comparison of prednisolone with aspirin or other analgesics in the treatment of rheumatoid arthritis</TI>
<SO>Ann Rheum Dis</SO>
<YR>1960</YR>
<VL>19</VL>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West HF</AU>
<TI>Reumatoid arthritis. The relevance of clinical knowledge to research activities</TI>
<SO>Abstracts World Med</SO>
<YR>1967</YR>
<VL>41</VL>
<PG>401-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirwan-1995" NAME="Kirwan 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Haugeberg G, Strand A, Kvien TK, Kirwan JR. Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial. Arch Intern Med 2005; 165(11):1293-7.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haugeberg G, Strand A, Kvien TK, Kirwan JR</AU>
<TI>Reduced loss of hand bone density with prednisolone in early rheumatoid arthritis: results from a randomized placebo-controlled trial</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2005</YR>
<VL>165</VL>
<NO>11</NO>
<PG>1293-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Hickling-P, Jacoby-RK, Kirwan-JR. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. Br-J-Rheumatol 1998; 37:930-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hickling P, Jacoby RK, Kirwan JR</AU>
<TI>Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group</TI>
<SO>Br J Rheumatol</SO>
<YR>1998</YR>
<VL>37</VL>
<PG>930-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirwan JR and the Arthritis and Rheumatism Council Low-dose Glucocorticoid Study Group</AU>
<TI>The effect of glucocorticoids on joint destruction in rheumatoid arthritis</TI>
<SO>N Engl J Med</SO>
<YR>1995</YR>
<VL>333</VL>
<PG>142-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kvien-1982" NAME="Kvien 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;Kvien TK, Hoyeraal HM, Sandstad B. Assessment methods of disease activity in juvenile rheumatoid arthritis - evaluated in a prednisolone/placebo double-blind study. J Rheumatol 1982; 9:696-702.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kvien TK, Hoyeraal HM, Sandstad B</AU>
<TI>Assessment methods of disease activity in juvenile rheumatoid arthritis - evaluated in a prednisolone/placebo double-blind study</TI>
<SO>J Rheumatol</SO>
<YR>1982</YR>
<VL>9</VL>
<PG>696-702</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leszczynski-2000" NAME="Leszczynski 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Leszczynski P, Lacki J K, Mackiewicz S H. Osteoporoza posteroidowa u chorych na reumatoidalne zapalenie stawow. Przegl Lek 2000; 57(2):108-10.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leszczynski P, Lacki J K, Mackiewicz S H</AU>
<TI>Osteoporoza posteroidowa u chorych na reumatoidalne zapalenie stawow</TI>
<SO>Przegl Lek</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>2</NO>
<PG>108-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Million-1984" NAME="Million 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Million R, Kellgren JH, Poole P, Jayson MIV</AU>
<TI>Long-term study of management of rheumatoid arthritis</TI>
<SO>Lancet</SO>
<YR>1984</YR>
<VL>i</VL>
<PG>812-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>West HF</AU>
<TI>Reumatoid arthritis. The relevance of clinical knowledge to research activities</TI>
<SO>Abstracts World Med</SO>
<YR>1967</YR>
<VL>41</VL>
<PG>401-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckner J, Uddin J, Ramsey RH</AU>
<TI>Adrenal-pituitary relationships with porlonged low dosage steroid therapy in rheumatoid arthritis</TI>
<SO>Missouri Med</SO>
<YR>1969</YR>
<VL>66</VL>
<PG>649-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murthy-1978" NAME="Murthy 1978" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murthy MHV, Rhymer AR, Wright V</AU>
<TI>Indomethacin or prednisolone at night in rheumatoid arthritis?</TI>
<SO>Rheumatol Rehab</SO>
<YR>1978</YR>
<VL>17</VL>
<PG>8-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rau-2000" NAME="Rau 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Rau R, Wassenberg S, Zeidler H. Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis--preliminary results of a multicenter, randomized, parallel, double blind study. Z Rheumatol 2000; 59 Suppl 2:II/90-6.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rau R, Wassenberg S, Zeidler H</AU>
<TI>Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis - preliminary results of a multicenter, randomized, parallel, double blind study</TI>
<SO>Z Rheumatol</SO>
<YR>2000</YR>
<VL>59 Suppl 2</VL>
<PG>II/90-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52(11):3371-80.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wassenberg S, Rau R, Steinfeld P, Zeidler H</AU>
<TI>Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years: a multicenter, double-blind, placebo-controlled trial</TI>
<SO>Arthritis Rheum</SO>
<YR>2005</YR>
<VL>52</VL>
<NO>11</NO>
<PG>3371-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siegmeth-1974" NAME="Siegmeth 1974" YEAR="1974">
<REFERENCE NOTES="&lt;p&gt;Siegmeth W, Herkner W. Erfahrungen mit einem neuen Kombinationspr&amp;#228;parat (Realin) bei der Behandlung akuter rheumatischer Zustandsbilder. Wien Med Wochenschr 1974; 124:569-73.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siegmeth W, Herkner W</AU>
<TI>Erfahrungen mit einem neuen Kombinationspräparat (Realin) bei der Behandlung akuter rheumatischer Zustandsbilder</TI>
<SO>Wien Med Wochenschr</SO>
<YR>1974</YR>
<VL>124</VL>
<PG>569-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Slonim-1969" NAME="Slonim 1969" YEAR="1969">
<REFERENCE NOTES="&lt;p&gt;Slonim RR, Kiem IM, Howell DS, Brown HE. Evaluation of drug responses in the patient severely afflicted with rheumatoid arthritis. J Florida Med Assoc 1969; 56,5:336-41.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Slonim RR, Kiem IM, Howell DS, Brown HE</AU>
<TI>Evaluation of drug responses in the patient severely afflicted with rheumatoid arthritis</TI>
<SO>J Florida Med Assoc</SO>
<YR>1969</YR>
<VL>56,5</VL>
<PG>336-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-van-Everdingen-2002" NAME="van Everdingen 2002" YEAR="2002">
<REFERENCE NOTES="&lt;p&gt;1. Huisman AM, Siewertsz van Everdingen AA, Wenting MJ, et al. Glucocorticoid receptor up-regulation in early rheumatoid arthritis treated with low dose prednisone or placebo. Clin Exp Rheumatol 2003; 21(2):217-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huisman AM, Siewertsz van Everdingen AA, Wenting MJ, et al</AU>
<TI>Glucocorticoid receptor up-regulation in early rheumatoid arthritis treated with low dose prednisone or placebo</TI>
<SO>Clin Exp Rheumatol</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>2</NO>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;van Everdingen AA, Jacobs JW G, Siewertsz Van Reesema DR, Bijlsma JW J. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann-Intern-Med 2002; 136(1):1-12.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Everdingen AA, Jacobs JW G, Siewertsz Van Reesema DR, Bijlsma JW J</AU>
<TI>Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial</TI>
<SO>Ann Intern Med</SO>
<YR>2002</YR>
<VL>136</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;2. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW. Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 2003; 21(2):155-60.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW</AU>
<TI>Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures?</TI>
<SO>Clin Exp Rheumatol</SO>
<YR>2003</YR>
<VL>21</VL>
<NO>2</NO>
<PG>155-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW. The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies. Arthritis Rheum 2004; 51(2):233-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW</AU>
<TI>The clinical effect of glucocorticoids in patients with rheumatoid arthritis may be masked by decreased use of additional therapies</TI>
<SO>Arthritis Rheum</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>2</NO>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Webb-1973" NAME="Webb 1973" YEAR="1973">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Webb J, Downie WW, Dick WC, Lee P</AU>
<TI>Evaluation of digital joint circumference measurements in rheumatoid arthritis</TI>
<SO>Scand J Rheumatol</SO>
<YR>1973</YR>
<VL>2</VL>
<PG>127-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zuckner-1969" NAME="Zuckner 1969" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zuckner J, Uddin J, Ramsey RH</AU>
<TI>Adrenal-pituitary relationships with porlonged low dosage steroid therapy in rheumatoid arthritis</TI>
<SO>Missouri Med</SO>
<YR>1969</YR>
<VL>66</VL>
<PG>649-58</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-09 00:09:18 -0500" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-09 00:09:18 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Arnett-1988" MODIFIED="2008-11-09 00:01:53 -0500" MODIFIED_BY="[Empty name]" NAME="Arnett 1988" TYPE="JOURNAL_ARTICLE">
<AU>Arnett FC, Edsworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al</AU>
<TI>The 1987 revised American Rheumatism Association criteria for classification of rheumatoid arthritis</TI>
<SO>Arthritis and Rheumatism</SO>
<YR>1988</YR>
<VL>31</VL>
<PG>315-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caldwell-1991" MODIFIED="2008-11-09 00:02:29 -0500" MODIFIED_BY="[Empty name]" NAME="Caldwell 1991" TYPE="JOURNAL_ARTICLE">
<AU>Caldwell JR, Furst DE</AU>
<TI>The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>1991</YR>
<VL>21</VL>
<PG>1-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Criswell-1998" MODIFIED="2008-11-08 23:59:06 -0500" MODIFIED_BY="[Empty name]" NAME="Criswell 1998" TYPE="COCHRANE_REVIEW">
<AU>Criswell LA, Saag KG, Sems KM, Welch V, Shea B, Wells G, Suarez-Almazor ME</AU>
<TI>Moderate-term, low-dose corticosteroids for rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1998</YR>
<NO>3</NO>
<PG>CD001158</PG>
<IDENTIFIERS MODIFIED="2008-11-08 23:56:13 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 23:56:13 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001158"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Da-Silva-2006" NAME="Da Silva 2006" TYPE="JOURNAL_ARTICLE">
<AU>Da Silva JA, Jacobs JW, Kirwan JR, Boers M, Saag KG, et al</AU>
<TI>Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data</TI>
<SO>Annals of the Rheumatic Diseases</SO>
<YR>2006</YR>
<VL>65</VL>
<NO>3</NO>
<PG>285-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1993" NAME="Dickersin 1993" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Min Y-I</AU>
<TI>NIH clinical trials and publication bias</TI>
<SO>Online J Curr Clin Trials</SO>
<YR>1993 Apr 28</YR>
<VL>Doc No 50</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1989a" MODIFIED="2008-11-09 00:02:51 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 1989a" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1989</YR>
<VL>10</VL>
<PG>31-56 (erratum: 356)</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1989b" MODIFIED="2008-11-09 00:03:24 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 1989b" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1989</YR>
<VL>36</VL>
<PG>493-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1990a" MODIFIED="2008-11-09 00:03:46 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 1990a" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1990</YR>
<VL>43</VL>
<PG>1313-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1990b" MODIFIED="2008-11-09 00:04:06 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 1990b" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Bias in double-blind trials (thesis)</TI>
<SO>Danish Medical Bulletin</SO>
<YR>1990</YR>
<VL>37</VL>
<PG>329-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-1994" MODIFIED="2008-11-09 00:04:25 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 1994" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC</AU>
<TI>Steroids and peptic ulcer: an end to the controversy? (editorial)</TI>
<SO>Journal of Internal Medicine</SO>
<YR>1994</YR>
<VL>236</VL>
<PG>599-601</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hench-1949" NAME="Hench 1949" TYPE="JOURNAL_ARTICLE">
<AU>Hench PS, Kendall EC, Slocumb CH, Polley HF</AU>
<TI>The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone: compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis</TI>
<SO>Proc Staff Meet Mayo Clin</SO>
<YR>1949</YR>
<VL>24</VL>
<PG>181-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kirwan-2007" MODIFIED="2008-11-08 23:54:39 -0500" MODIFIED_BY="[Empty name]" NAME="Kirwan 2007" TYPE="COCHRANE_REVIEW">
<AU>Kirwan JR, Bijlsma JWJ, Boers M, Shea B</AU>
<TI>Effects of glucocorticoids on radiological progression in rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2008-11-08 23:54:36 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 23:54:36 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006356"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-McDougall-1994" MODIFIED="2008-11-09 00:07:08 -0500" MODIFIED_BY="[Empty name]" NAME="McDougall 1994" TYPE="JOURNAL_ARTICLE">
<AU>McDougall R, Sibley J, Haga M, Russell A</AU>
<TI>Outcome in patients with rheumatoid arthritis receiving prednisone compared to matched controls</TI>
<SO>Journal of Rheumatology</SO>
<YR>1994</YR>
<VL>21</VL>
<PG>1207-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Saag-1994" MODIFIED="2008-11-09 00:07:46 -0500" MODIFIED_BY="[Empty name]" NAME="Saag 1994" TYPE="JOURNAL_ARTICLE">
<AU>Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B et al</AU>
<TI>Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events</TI>
<SO>American Journal of Medicine</SO>
<YR>1994</YR>
<VL>96</VL>
<PG>115-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savulescu-1996" NAME="Savulescu 1996" TYPE="JOURNAL_ARTICLE">
<AU>Savulescu J, Chalmers I, Blunt J</AU>
<TI>Are research ethics committees behaving unethically? Some suggestions for improving performance and accountability</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1390-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman D</AU>
<TI>Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stern-1997" NAME="Stern 1997" TYPE="JOURNAL_ARTICLE">
<AU>Stern JM, Simes RJ</AU>
<TI>Publication bias: evidence of delayed publication in a cohort study of clinical research projects</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>640-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stuck-1989" MODIFIED="2008-11-09 00:08:47 -0500" MODIFIED_BY="[Empty name]" NAME="Stuck 1989" TYPE="JOURNAL_ARTICLE">
<AU>Stuck AE, Minder CE, Frey FJ</AU>
<TI>Risk of infectious complications in patients taking glucocorticosteroids</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1989</YR>
<VL>11</VL>
<PG>954-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weiss-1989" MODIFIED="2008-11-09 00:09:18 -0500" MODIFIED_BY="[Empty name]" NAME="Weiss 1989" TYPE="JOURNAL_ARTICLE">
<AU>Weiss MM</AU>
<TI>Corticosteroids in rheumatoid arthritis</TI>
<SO>Seminars in Arthritis and Rheumatism</SO>
<YR>1989</YR>
<VL>19</VL>
<PG>9-21</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-11-09 00:00:31 -0500" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-G_x00f8_tzsche-1998" MODIFIED="2008-11-09 00:00:31 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 1998" TYPE="JOURNAL_ARTICLE">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Meta-analysis of short-term low-dose prednisolone vs placebo and nonsteroidal, antiinflammatory drugs in rheumatoid arthritis</TI>
<SO>BMJ</SO>
<YR>1998</YR>
<VL>316</VL>
<PG>811-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-G_x00f8_tzsche-2001" MODIFIED="2008-11-08 23:52:12 -0500" MODIFIED_BY="[Empty name]" NAME="Gøtzsche 2001" TYPE="COCHRANE_REVIEW">
<AU>Gøtzsche PC, Johansen HK</AU>
<TI>Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2001</YR>
<NO>2</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-11-08 23:52:08 -0500" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 23:52:08 -0500" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000189.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Berry-1974">
<CHAR_METHODS>
<P>Crossover study; one-week periods, and one-week wash-out.<BR/>Randomisation not mentioned; only that the study was double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>12 patients with definite or classical rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisolone 15 mg/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (visual analogue scale)<BR/>Duration of morning stiffness<BR/>Ritchie's index<BR/>Joint size<BR/>Paracetamol consumption<BR/>Technetium index<BR/>Indium index<BR/>Patient preference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. No data on side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Boardman-1967">
<CHAR_METHODS>
<P>Crossover study; one-week periods. Sequential analysis of joint size.<BR/>Randomisation not mentioned; only that the study was double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>13 patients with definite or classical rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisone 7.5 mg/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Joint size<BR/>Grip strength<BR/>Patient preference</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. We included two patients, who the authors had excluded because of too little difference in joint size, in the analysis by assuming that their grip strength difference was zero. Grip strength data were missing for another patient. Two patients on prednisone had 'subjective reactions'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-B_x00f6_hm-1967">
<CHAR_METHODS>
<P>Four-way crossover study; eight-day periods.<BR/>Randomisation method not described.<BR/>Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>20 patients with rheumatoid arthritis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisolone 2.5 mg, two combination drugs, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Pain (4 point ranking scale)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. No data on side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dick-1970">
<CHAR_METHODS>
<P>Four-way crossover study; one-week periods.<BR/>Randomisation method not described.<BR/>Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 patients with definite or classical rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisolone 10 mg/d, ibuprofen 1200 mg/d, aspirin 4 g/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global evaluation<BR/>Knee tenderness score<BR/>Ritchie's index<BR/>Grip strength<BR/>Joint size</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. Average of ibuprofen and aspirin used in the analysis. No data on side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jasani-1968">
<CHAR_METHODS>
<P>Four-way crossover study; one-week periods.<BR/>Randomisation method not described.<BR/>Double-blind.</P>
<P>
<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>9 patients with definite or classical rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisolone 15 mg/d, ibuprofen 750 mg/d, aspirin 5 g/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Joint pain<BR/>Joint stiffness<BR/>Pain index (composite scale)<BR/>Ritchie's index<BR/>Grip strength<BR/>Joint size</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. Average of ibuprofen and aspirin used in the analysis. No side effects occurred with prednisolone or placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kirwan-2004">
<CHAR_METHODS>
<P>Group comparative study; 12 weeks, data after 2 weeks available.<BR/>Randomisation method: "Predefined sequence of randomly generated allocations kept in sealed envelopes", "Patients allocated to next available study number".<BR/>Double-blind: "double-dummy".</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>143 patients with rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Budesonide 3 and 9 mg, 7.5 mg prednisolone, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joint count<BR/>Pain<BR/>Global assessments<BR/>Physical function (HAQ)<BR/>SF-36</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Data after 2 weeks from author; SDs estimated from graphs after 4 weeks.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1973a">
<CHAR_METHODS>
<P>Three-way crossover study; one-week periods.<BR/>Randomisation method not described.<BR/>Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>21 patients with definite or classical rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisolone 15 mg/d, aspirin 5 g/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Functional index<BR/>Ritchie's index<BR/>Time to walk 50 feet<BR/>Grip strength</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. No data on side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1973b">
<CHAR_METHODS>
<P>Group comparative study of three drugs; two weeks.<BR/>Randomisation method not described.<BR/>Single-blind; probably the patient was blinded.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>141 patients with rheumatoid arthritis according to ARA criteria.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisone 15 mg/d, aspirin 3.9 g/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Global evaluation<BR/>Pain (5 point ranking scale)<BR/>Number of days withdrawn from trial</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Thirteen patients were excluded after randomisation (failed to complete the trial), three on prednisolone, five on aspirin, and five on placebo. One patient developed acute psychosis on prednisone.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lee-1974">
<CHAR_METHODS>
<P>Three-way crossover study; one-week periods.<BR/>Randomisation method not described.<BR/>Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 patients with definite or classical rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisolone 10 mg/d, sodium salicylate 4 g/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Functional index<BR/>Ritchie's index<BR/>Grip strength</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No test for carry-over and period effects. No data on side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Stenberg-1992">
<CHAR_METHODS>
<P>Crossover study; each flare treated for five days. <BR/>Randomisation not described; only that the study was double-blind, half of the patients starting on each drug.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>22 patients with rheumatoid arthritis (ARA criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisone (average dose 3 mg/d), placebo. Prednisone was only taken during flares: 7.5 mg day 1, 5 mg next 3 days, and 2.5 mg day 5.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Tender joint count<BR/>Swollen joint count<BR/>Pain (composite score)<BR/>Global assessment<BR/>Morning stiffness<BR/>Painful joint count<BR/>Time until fatigue<BR/>Medication usage</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Tested for carry-over effects. Three randomised patients were excluded because of poor response to prednisone in an introductory test period. We included these patients in the analysis by assuming that the differences between prednisone and placebo were zero. One additional patient dropped out for personal reasons. No data on short-term side effects since multiple flares were treated during a three months period.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-van-Gestel-1995">
<CHAR_METHODS>
<P>Group comparative study; 44 weeks, data after one week provided by authors. <BR/>Randomisation method: list of random numbers; a pharmacist coded the packages.<BR/>Double-blind.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>40 patients with definite or classical rheumatoid arthritis (ARA criteria); all started parenteral gold.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prednisone 10 mg/d, placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Joint pain (visual analogue scale)<BR/>Global evaluation<BR/>Morning stiffness<BR/>Ritchie's index<BR/>Number of swollen joints<BR/>Grip strength<BR/>Functional capacity<BR/>X-ray progression</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Grip strength recalculated as mm Hg from kPa. Long-term study, no data on short-term side effects.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Badia-Flores-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination drug (prednisolone 2.5 mg + oxiphenbutazone 100 mg) vs placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Capell-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term study with assessment after 1 and 2 years (7 mg prednisolone vs placebo, 167 patients).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chamberlain-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term study with assessment after 1, 2, and 3 years (3 and 5 mg prednisolone vs placebo, 49 patients).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Deodhar-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Unbalanced design (five-way crossover trial comparing prednisolone 10 mg with placebo and three NSAIDs).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Empire-Rheum-1955">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term study with assessment after 6 and 12 months (75 mg cortisone vs aspirin 4 g, 100 patients).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fearnley-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data on dispersion (prednisone 7.5 mg vs flufenamic acid 600 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gum-1966">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only 50 of 68 patients had rheumatoid arthritis; combination drug (paramethasone 1.5 g + aspirin 3 g + propoxyphene 192 mg vs aspirin 3 g + propoxyphene 192 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hansen-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Dose of prednisolone too high, 30 mg daily in first week.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hantzschel-1976">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Harris-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term study with assessment after 12 and 24 weeks (prednisone 5 mg vs placebo, 34 patients).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jick-1965">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination drug (dexamethasone 1.5 mg vs dexamethasone 0.75 mg + aspirin 1.5 g).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joint-Committee-1954">
<CHAR_REASON_FOR_EXCLUSION>
<P>Cortisone dose too high (300-100 mg in the first week, average dose corresponding to 16 mg prednisolone, comparison with aspirin 6 g, 62 patients).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joint-Committee-1959">
<CHAR_REASON_FOR_EXCLUSION>
<P>Prednisolone dose 20 mg initially with an average of 17.4 mg after 4 weeks. Long-term study vs aspirin or other analgesics, 84 patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kirwan-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term study with no short-term data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kvien-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Juvenile rheumatoid arthritis (prednisolone 0.4 mg/kg vs placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leszczynski-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerns osteoporosis, no clinical outcomes.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Million-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Randomised to activity + steroid and to rest; therefore, not valid for testing the effect of steroid versus no steroid. Further, the dose was up to 20 mg prednisolone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Murthy-1978">
<CHAR_REASON_FOR_EXCLUSION>
<P>No data presented on the original interval scales, only data on reduced (trinomial) scales shown.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rau-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Concerns radiological progression, no clinical data.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siegmeth-1974">
<CHAR_REASON_FOR_EXCLUSION>
<P>Combination drug (prednisolone 2.5 mg + oxiphenbutazone 100 mg vs flufenamic acid 200 mg).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Slonim-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Stepwise increasing dose of methylprednisolone up to 16 mg but placebo group received 4 mg methylprednisolone daily.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-van-Everdingen-2002">
<CHAR_REASON_FOR_EXCLUSION>
<P>Long-term study with assessments every 3 months (10 mg prednisolone vs placebo, 81 patients with early disease).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Webb-1973">
<CHAR_REASON_FOR_EXCLUSION>
<P>Only joint size recorded (prednisolone 7.5 mg vs aspirin 4.8 g vs placebo).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Zuckner-1969">
<CHAR_REASON_FOR_EXCLUSION>
<P>Describes an unpublished crossover trial of 20 patients; combination therapy, steroid + analgesics versus analgesics.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Berry-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Boardman-1967">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-B_x00f6_hm-1967">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dick-1970">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jasani-1968">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Kirwan-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1973a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1973b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Lee-1974">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stenberg-1992">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Gestel-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES>
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Harms in moderate- and long-term studies</TITLE>
<TABLE COLS="5" ROWS="13">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Drugs</P>
</TH>
<TH>
<P>Length of study</P>
</TH>
<TH>
<P>Number of patients</P>
</TH>
<TH>
<P>Harms</P>
</TH>
</TR>
<TR>
<TD>
<P>Capell 2004</P>
</TD>
<TD>
<P>Prednisolone 7 mg, placebo</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>84 vs 83</P>
</TD>
<TD>
<P>Withdrawals: 6 (3 weight gain, facial swelling, nausea, gastrointesinal bleeding) vs 2 (nausea, diarrhoea); Fractures: none reported; No difference in bone mineral content, blood pressure or weight.</P>
</TD>
</TR>
<TR>
<TD>
<P>Chamberlain 1976</P>
</TD>
<TD>
<P>Prednisolone 3 and 5 mg, placebo</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>20 vs 10 vs 19</P>
</TD>
<TD>
<P>Withdrawals: none because of harms; Vertebral fractures: 1 vs 0 vs 1; Moon face (difficult to decide): 5 vs 2 vs 1; Mild dyspepsia: 3 vs 4 vs 4.</P>
</TD>
</TR>
<TR>
<TD>
<P>Empire Rheum 1955</P>
</TD>
<TD>
<P>Cortisone 75 mg, Aspirin 4 g</P>
</TD>
<TD>
<P>3 years</P>
</TD>
<TD>
<P>50 vs 50</P>
</TD>
<TD>
<P>Withdrawals: 3 (2 hypertension, indigestion) vs 5(gastrointestinal symptoms); Fractures: 1 (after a fall) vs 0; Oedema: 4 vs 0; Gastrointestinal symptoms: 4 vs 17; Mild psychiatric disturbance: 4 vs 0; Infection: 10 vs 4. (These are 1-year data)</P>
</TD>
</TR>
<TR>
<TD>
<P>Harris 1983</P>
</TD>
<TD>
<P>Prednisone 5 mg, placebo</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>18 vs 16</P>
</TD>
<TD>
<P>Withdrawals: none reported; Vertebral fractures detected with X-ray: 2 vs 0; Ocular changes: none.</P>
</TD>
</TR>
<TR>
<TD>
<P>Joint Committee 1954</P>
</TD>
<TD>
<P>Cortisone 80 mg, Aspirin 4.5 g</P>
</TD>
<TD>
<P>1 year</P>
</TD>
<TD>
<P>30 vs 31</P>
</TD>
<TD>
<P>Withdrawals: none because of harms; Fractures: none reported; Most common harms on steroid: 11 moon face or rubicundity, 5 depression, 4 euphoria; on Aspirin: 13 gastrointestinal symptoms, 11 tinnitus, 10 deafness.</P>
</TD>
</TR>
<TR>
<TD>
<P>Joint Committee 1959</P>
</TD>
<TD>
<P>Prednisolone 17.4 mg, NSAIDs</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>45 vs 39</P>
</TD>
<TD>
<P>Withdrawals: none because of harms; Vertebral fractures detected with X-ray: 2 vs 1; Acute phychosis: 2 vs 0; Peptic ulcer: 3 vs 0; Major infection: 4 vs 3.</P>
</TD>
</TR>
<TR>
<TD>
<P>Kirwan 1995</P>
</TD>
<TD>
<P>Prednisolone 7.5 mg, placebo</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>61 vs 67</P>
</TD>
<TD>
<P>Withdrawals: 1 vs 2 hypertension and weight gain, 0 vs 1 diabetes; Fractures: none reported; Other harms: only listed, not divided on treatment groups.</P>
</TD>
</TR>
<TR>
<TD>
<P>Kirwan 2004</P>
</TD>
<TD>
<P>Budesonide 3 and 9 mg, prednisolone 7.5 mg, placebo</P>
</TD>
<TD>
<P>12 weeks</P>
</TD>
<TD>
<P>37, 36, 39, 31</P>
</TD>
<TD>
<P>Withdrawals: no data, only symptoms listed; Serious harms: budesonide 3 mg (1 angina), prednisolone (1 with ischaemic heart diesase died); Fractures: none reported; Respiratory infection: 7 vs 4 vs 6 vs 1; Viral infection: 4 vs 1 vs 0 vs 0. Abdominal pain: 4 vs 3 vs 4 vs 2.</P>
</TD>
</TR>
<TR>
<TD>
<P>Rau 2000</P>
</TD>
<TD>
<P>Prednisolone 5 mg, placebo</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>80 vs 86</P>
</TD>
<TD>
<P>Withdrawals: none; Vertebral fractures detected with X-ray: none; Other fractures: 1 (pubic ramus) vs 0 (plus 4 caused by trauma, not divided on treatment groups); Cushing: 5 vs 0; Hypertension: 6 vs 2; Weight gain: 5 kg vs 0.3 kg; Cataract: 5 vs 6; Gastric ulcers: 3 vs 0. Headache: 4 vs 0.</P>
</TD>
</TR>
<TR>
<TD>
<P>Stenberg 1992</P>
</TD>
<TD>
<P>Prednisolone 3 mg, placebo</P>
</TD>
<TD>
<P>3 months</P>
</TD>
<TD>
<P>18 (crossover)</P>
</TD>
<TD>
<P>Withdrawals: none reported; Fractures: none reported; Weight gain: 3 vs 2; Hypertension: 1 vs 3; Gastrointestinal symptoms: 2 vs 2; Insomnia: 1 vs 0.</P>
</TD>
</TR>
<TR>
<TD>
<P>van Everdingen 2002</P>
</TD>
<TD>
<P>Prednisolone 10 mg, placebo</P>
</TD>
<TD>
<P>2 years</P>
</TD>
<TD>
<P>40 vs 41</P>
</TD>
<TD>
<P>Withdrawals: none because of harms; Vertebral fractures detected with X-ray: 5 vs 2; Respiratory infections: 13 vs 13; Diabetes: 2 vs 1; Peptic ulcer: 1 vs 2; Depression: 1 vs 2.</P>
</TD>
</TR>
<TR>
<TD>
<P>van Gestel 1995</P>
</TD>
<TD>
<P>Prednisolone 10 mg (tapered to 2.5 mg), placebo</P>
</TD>
<TD>
<P>44 weeks</P>
</TD>
<TD>
<P>20 vs 20</P>
</TD>
<TD>
<P>Withdrawals: none reported; Vertebral fractures detected with X-ray: none; Other harms: none reported.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Oral corticosteroids vs placebo</NAME>
<CONT_OUTCOME CHI2="33.207866366090364" CI_END="-0.6370247318303548" CI_START="-1.6884358668461488" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.1627302993382518" ESTIMABLE="YES" I2="78.92065716348483" I2_Q="92.23495859802729" ID="CMP-001.01" NO="1" P_CHI2="2.421699115995324E-5" P_Q="3.324289492622201E-4" P_Z="1.4579053283787898E-5" Q="12.878231399332257" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.4356448250456177" TOTALS="YES" TOTAL_1="236" TOTAL_2="156" UNITS="" WEIGHT="100.0" Z="4.334954109844418">
<NAME>Joint tenderness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.7530785335882242" CI_END="-0.03296535376972398" CI_START="-1.009364216507275" DF="1.0" EFFECT_SIZE="-0.5211647851384995" ESTIMABLE="YES" I2="42.95748987621297" ID="CMP-001.01.01" NO="1" P_CHI2="0.18549029994440902" P_Z="0.036410856619960616" STUDIES="2" TAU2="0.057069507747577554" TOTAL_1="131" TOTAL_2="51" WEIGHT="28.260070481950386" Z="2.092309296670242">
<NAME>Allocation concealment</NAME>
<CONT_DATA CI_END="0.0704186178734102" CI_START="-0.7296748723261212" EFFECT_SIZE="-0.3296281272263555" ESTIMABLE="YES" MEAN_1="9.72" MEAN_2="11.28" ORDER="139579" SD_1="4.72" SD_2="4.66" SE="0.2041092327488073" STUDY_ID="STD-Kirwan-2004" TOTAL_1="111" TOTAL_2="31" WEIGHT="15.072754289658894"/>
<CONT_DATA CI_END="-0.1953324548458435" CI_START="-1.494850074682324" EFFECT_SIZE="-0.8450912647640837" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="16.3" ORDER="139580" SD_1="4.7" SD_2="7.7" SE="0.3315156885756344" STUDY_ID="STD-van-Gestel-1995" TOTAL_1="20" TOTAL_2="20" WEIGHT="13.18731619229149"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="18.576556433169884" CI_END="-0.7850903305077057" CI_START="-2.00509277076116" DF="5.0" EFFECT_SIZE="-1.395091550634433" ESTIMABLE="YES" I2="73.08435490728459" ID="CMP-001.01.02" NO="2" P_CHI2="0.0023042224097320485" P_Z="7.377436549183242E-6" STUDIES="6" TAU2="0.41541733405023445" TOTAL_1="105" TOTAL_2="105" WEIGHT="71.7399295180496" Z="4.482497910105116">
<NAME>Allocation concealment unclear</NAME>
<CONT_DATA CI_END="-0.0878915263181731" CI_START="-1.7904783796379395" EFFECT_SIZE="-0.9391849529780564" ESTIMABLE="YES" MEAN_1="13.0" MEAN_2="23.7" ORDER="139581" SD_1="11.0" SD_2="11.0" SE="0.43434136207337337" STUDY_ID="STD-Berry-1974" TOTAL_1="12" TOTAL_2="12" WEIGHT="11.523848848494238"/>
<CONT_DATA CI_END="-1.3886380606870596" CI_START="-2.821539655328299" EFFECT_SIZE="-2.1050888580076794" ESTIMABLE="YES" MEAN_1="17.6" MEAN_2="40.7" ORDER="139582" SD_1="8.0" SD_2="13.0" SE="0.3655428380173779" STUDY_ID="STD-Dick-1970" TOTAL_1="24" TOTAL_2="24" WEIGHT="12.63785669149068"/>
<CONT_DATA CI_END="-0.7440194379044422" CI_START="-3.067690566526161" EFFECT_SIZE="-1.9058550022153016" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="38.1" ORDER="139583" SD_1="8.7" SD_2="12.8" SE="0.5927841396450496" STUDY_ID="STD-Jasani-1968" TOTAL_1="9" TOTAL_2="9" WEIGHT="9.140992357314351"/>
<CONT_DATA CI_END="0.032255992594449334" CI_START="-1.2058560121919224" EFFECT_SIZE="-0.5868000097987365" ESTIMABLE="YES" MEAN_1="30.5" MEAN_2="41.4" ORDER="139584" SD_1="16.5" SD_2="19.8" SE="0.31585070301098417" STUDY_ID="STD-Lee-1973a" TOTAL_1="21" TOTAL_2="21" WEIGHT="13.43709347394316"/>
<CONT_DATA CI_END="-0.15054522500019818" CI_START="-1.5196462573445484" EFFECT_SIZE="-0.8350957411723733" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="26.4" ORDER="139585" SD_1="12.4" SD_2="15.1" SE="0.34926688529576166" STUDY_ID="STD-Lee-1974" TOTAL_1="18" TOTAL_2="18" WEIGHT="12.901527752913642"/>
<CONT_DATA CI_END="-1.421462503978161" CI_START="-2.9844980742617255" EFFECT_SIZE="-2.2029802891199433" ESTIMABLE="YES" MEAN_1="6.3" MEAN_2="11.1" ORDER="139586" SD_1="1.7" SD_2="2.5" SE="0.3987408908052877" STUDY_ID="STD-Stenberg-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="12.09861039389353"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="64.91745464924068" CI_END="-0.714751233549104" CI_START="-2.312298370800935" CI_STUDY="95" CI_TOTAL="95" DF="6.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.5135248021750196" ESTIMABLE="YES" I2="90.75749344699518" I2_Q="93.14176306246164" ID="CMP-001.02" NO="2" P_CHI2="4.485412041788095E-12" P_Q="1.342631206323608E-4" P_Z="2.042016799240756E-4" Q="14.58100688424058" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="1.0133683215865619" TOTALS="YES" TOTAL_1="250" TOTAL_2="166" UNITS="" WEIGHT="100.0" Z="3.7137609686737254">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="5.3230599412998565" CI_END="0.22816892165104197" CI_START="-1.577549779270969" DF="1.0" EFFECT_SIZE="-0.6746904288099634" ESTIMABLE="YES" I2="81.2138129003333" ID="CMP-001.02.01" NO="1" P_CHI2="0.021045086634473353" P_Z="0.14301764429930677" STUDIES="2" TAU2="0.34754085030409637" TOTAL_1="131" TOTAL_2="51" WEIGHT="30.409433474414463" Z="1.4646455624635268">
<NAME>Allocation concealment</NAME>
<CONT_DATA CI_END="0.1451160385566263" CI_START="-0.6534438831880711" EFFECT_SIZE="-0.2541639223157224" ESTIMABLE="YES" MEAN_1="44.31" MEAN_2="50.03" ORDER="139587" SD_1="22.35" SD_2="22.51" SE="0.20371800911742158" STUDY_ID="STD-Kirwan-2004" TOTAL_1="111" TOTAL_2="31" WEIGHT="15.745357144679664"/>
<CONT_DATA CI_END="-0.5023725606263658" CI_START="-1.8562161904394763" EFFECT_SIZE="-1.179294375532921" ESTIMABLE="YES" MEAN_1="35.6" MEAN_2="58.3" ORDER="139588" SD_1="16.2" SD_2="21.2" SE="0.34537461925118423" STUDY_ID="STD-van-Gestel-1995" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.664076329734797"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="45.01338782370024" CI_END="-0.7860631484676113" CI_START="-2.99825065038846" DF="4.0" EFFECT_SIZE="-1.8921568994280356" ESTIMABLE="YES" I2="91.11375483297007" ID="CMP-001.02.02" NO="2" P_CHI2="3.9505865245814675E-9" P_Z="7.998588527306686E-4" STUDIES="5" TAU2="1.4098397312474669" TOTAL_1="119" TOTAL_2="115" WEIGHT="69.59056652558554" Z="3.3528436199533496">
<NAME>Allocation concealment unclear</NAME>
<CONT_DATA CI_END="0.171798140821028" CI_START="-1.085604703639285" EFFECT_SIZE="-0.45690328140912856" ESTIMABLE="YES" MEAN_1="2.15" MEAN_2="2.6" ORDER="139589" SD_1="0.99" SD_2="0.94" SE="0.3207719260094946" STUDY_ID="STD-B_x00f6_hm-1967" TOTAL_1="20" TOTAL_2="20" WEIGHT="14.879374646185983"/>
<CONT_DATA CI_END="-3.535603472193923" CI_START="-5.7871223329967005" EFFECT_SIZE="-4.661362902595312" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="2.83" ORDER="139590" SD_1="0.59" SD_2="0.39" SE="0.5743776106506218" STUDY_ID="STD-Dick-1970" TOTAL_1="24" TOTAL_2="24" WEIGHT="12.364748859091096"/>
<CONT_DATA CI_END="-0.5565705939063879" CI_START="-2.7776861643320405" EFFECT_SIZE="-1.6671283791192142" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="25.1" ORDER="139591" SD_1="5.7" SD_2="14.6" SE="0.5666215267080233" STUDY_ID="STD-Jasani-1968" TOTAL_1="9" TOTAL_2="9" WEIGHT="12.44674961967978"/>
<CONT_DATA CI_END="-0.6319309047814505" CI_START="-1.541203423576759" EFFECT_SIZE="-1.0865671641791048" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="3.47" ORDER="139592" SD_1="0.83" SD_2="0.83" SE="0.2319615375505709" STUDY_ID="STD-Lee-1973b" TOTAL_1="45" TOTAL_2="41" WEIGHT="15.563804236462772"/>
<CONT_DATA CI_END="-1.2035290156461809" CI_START="-2.697289488803912" EFFECT_SIZE="-1.9504092522250465" ESTIMABLE="YES" MEAN_1="23.5" MEAN_2="39.7" ORDER="139593" SD_1="5.9" SD_2="9.9" SE="0.3810683474136063" STUDY_ID="STD-Stenberg-1992" TOTAL_1="21" TOTAL_2="21" WEIGHT="14.335889164165923"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9711827872982703" CI_END="0.6859343231653664" CI_START="0.13422812274180995" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.4100812229535882" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="0.8531179430391376" P_Q="0.503878345639693" P_Z="0.0035720925636525667" Q="0.44675850913272397" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="104" UNITS="" WEIGHT="100.00000000000001" Z="2.9136682789068584">
<NAME>Grip strength</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8418845333844136" CI_START="-0.4018585333983702" DF="0.0" EFFECT_SIZE="0.22001299999302174" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.01" NO="1" P_CHI2="1.0" P_Z="0.4880466273337648" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="19.67679604767503" Z="0.693419031042116">
<NAME>Allocation concealment</NAME>
<CONT_DATA CI_END="0.8418845333844136" CI_START="-0.4018585333983702" EFFECT_SIZE="0.22001299999302174" ESTIMABLE="YES" MEAN_1="191.0" MEAN_2="160.0" ORDER="139594" SD_1="112.0" SD_2="160.0" SE="0.3172872248146574" STUDY_ID="STD-van-Gestel-1995" TOTAL_1="20" TOTAL_2="20" WEIGHT="19.67679604767503"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="1.5244242781655464" CI_END="0.7644343058533742" CI_START="0.1488502635328129" DF="4.0" EFFECT_SIZE="0.4566422846930936" ESTIMABLE="YES" I2="0.0" ID="CMP-001.03.02" NO="2" P_CHI2="0.8223065059384812" P_Z="0.0036396291672684566" STUDIES="5" TAU2="0.0" TOTAL_1="84" TOTAL_2="84" WEIGHT="80.32320395232499" Z="2.9078155711855924">
<NAME>Allocation concealment unclear</NAME>
<CONT_DATA CI_END="1.6386857252076563" CI_START="0.024719847547761464" EFFECT_SIZE="0.8317027863777089" ESTIMABLE="YES" MEAN_1="372.0" MEAN_2="299.0" ORDER="139595" SD_1="85.0" SD_2="85.0" SE="0.41173355489964397" STUDY_ID="STD-Boardman-1967" TOTAL_1="13" TOTAL_2="13" WEIGHT="11.684954681953972"/>
<CONT_DATA CI_END="1.0751915328274806" CI_START="-0.07548403834254569" EFFECT_SIZE="0.49985374724246745" ESTIMABLE="YES" MEAN_1="213.0" MEAN_2="149.0" ORDER="139596" SD_1="136.0" SD_2="115.0" SE="0.2935450804827049" STUDY_ID="STD-Dick-1970" TOTAL_1="24" TOTAL_2="24" WEIGHT="22.988463423458484"/>
<CONT_DATA CI_END="1.6165458235726289" CI_START="-0.4024217647803783" EFFECT_SIZE="0.6070620293961253" ESTIMABLE="YES" MEAN_1="356.0" MEAN_2="267.0" ORDER="139597" SD_1="151.0" SD_2="125.0" SE="0.5150522163362097" STUDY_ID="STD-Jasani-1968" TOTAL_1="8" TOTAL_2="8" WEIGHT="7.4671871414174715"/>
<CONT_DATA CI_END="0.8579719786198106" CI_START="-0.35696836561298606" EFFECT_SIZE="0.25050180650341225" ESTIMABLE="YES" MEAN_1="109.0" MEAN_2="97.0" ORDER="139598" SD_1="47.0" SD_2="47.0" SE="0.3099394564941221" STUDY_ID="STD-Lee-1973a" TOTAL_1="21" TOTAL_2="21" WEIGHT="20.620814815477072"/>
<CONT_DATA CI_END="0.9868707616092955" CI_START="-0.3296373840934858" EFFECT_SIZE="0.3286166887579049" ESTIMABLE="YES" MEAN_1="73.1" MEAN_2="59.2" ORDER="139599" SD_1="43.5" SD_2="39.1" SE="0.33585008604424105" STUDY_ID="STD-Lee-1974" TOTAL_1="18" TOTAL_2="18" WEIGHT="17.56178389001798"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Oral corticosteroids vs NSAIDs</NAME>
<CONT_OUTCOME CHI2="6.734681967011821" CI_END="-0.10910048302810427" CI_START="-1.155175738846332" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.6321381109372181" ESTIMABLE="YES" I2="55.454466674228115" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.08085282652290937" P_Q="1.0" P_Z="0.017846233099654277" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.1550650213876349" TOTALS="YES" TOTAL_1="72" TOTAL_2="72" UNITS="" WEIGHT="100.0" Z="2.368793112734565">
<NAME>Joint tenderness</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="6.734681967011821" CI_END="-0.10910048302810427" CI_START="-1.155175738846332" DF="3.0" EFFECT_SIZE="-0.6321381109372181" ESTIMABLE="YES" I2="55.454466674228115" ID="CMP-002.01.01" NO="1" P_CHI2="0.08085282652290937" P_Z="0.017846233099654277" STUDIES="4" TAU2="0.1550650213876349" TOTAL_1="72" TOTAL_2="72" WEIGHT="100.0" Z="2.368793112734565">
<NAME>Allocation concealment unclear</NAME>
<CONT_DATA CI_END="-0.4973586401033916" CI_START="-1.7199865081576668" EFFECT_SIZE="-1.1086725741305292" ESTIMABLE="YES" MEAN_1="17.6" MEAN_2="28.7" ORDER="139600" SD_1="8.0" SD_2="11.4" SE="0.3119005955461957" STUDY_ID="STD-Dick-1970" TOTAL_1="24" TOTAL_2="24" WEIGHT="28.22094382009869"/>
<CONT_DATA CI_END="-0.1324970530137055" CI_START="-2.1663535216989382" EFFECT_SIZE="-1.149425287356322" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="26.7" ORDER="139601" SD_1="8.7" SD_2="8.7" SE="0.5188504698882309" STUDY_ID="STD-Jasani-1968" TOTAL_1="9" TOTAL_2="9" WEIGHT="16.785199601622597"/>
<CONT_DATA CI_END="0.24188010563830176" CI_START="-0.9791204000794707" EFFECT_SIZE="-0.36862014722058445" ESTIMABLE="YES" MEAN_1="30.5" MEAN_2="37.7" ORDER="139602" SD_1="16.5" SD_2="21.5" SE="0.31148544446450765" STUDY_ID="STD-Lee-1973a" TOTAL_1="21" TOTAL_2="21" WEIGHT="28.249916072314885"/>
<CONT_DATA CI_END="0.5706572848135227" CI_START="-0.7366166404911898" EFFECT_SIZE="-0.08297967783883349" ESTIMABLE="YES" MEAN_1="14.6" MEAN_2="15.7" ORDER="139603" SD_1="12.4" SD_2="13.5" SE="0.3334943742885896" STUDY_ID="STD-Lee-1974" TOTAL_1="18" TOTAL_2="18" WEIGHT="26.743940505963824"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="12.192254959181323" CI_END="-0.25990327636946153" CI_START="-2.2354382173489435" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.2476707468592025" ESTIMABLE="YES" I2="83.59614356248424" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.0022515781042004024" P_Q="1.0" P_Z="0.013298513839045666" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.62043158701509" TOTALS="YES" TOTAL_1="78" TOTAL_2="75" UNITS="" WEIGHT="100.0" Z="2.4756734772767817">
<NAME>Pain</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="12.192254959181323" CI_END="-0.25990327636946153" CI_START="-2.2354382173489435" DF="2.0" EFFECT_SIZE="-1.2476707468592025" ESTIMABLE="YES" I2="83.59614356248424" ID="CMP-002.02.01" NO="1" P_CHI2="0.0022515781042004024" P_Z="0.013298513839045666" STUDIES="3" TAU2="0.62043158701509" TOTAL_1="78" TOTAL_2="75" WEIGHT="100.0" Z="2.4756734772767817">
<NAME>Allocation concealment unclear</NAME>
<CONT_DATA CI_END="-1.266628447119942" CI_START="-2.6645510733889113" EFFECT_SIZE="-1.9655897602544266" ESTIMABLE="YES" MEAN_1="0.46" MEAN_2="1.69" ORDER="139604" SD_1="0.59" SD_2="0.64" SE="0.35661946783094084" STUDY_ID="STD-Dick-1970" TOTAL_1="24" TOTAL_2="24" WEIGHT="33.97337695923757"/>
<CONT_DATA CI_END="-0.2923432350909414" CI_START="-2.3892393184556395" EFFECT_SIZE="-1.3407912767732906" ESTIMABLE="YES" MEAN_1="5.7" MEAN_2="16.9" ORDER="139605" SD_1="5.7" SD_2="9.7" SE="0.534932299752635" STUDY_ID="STD-Jasani-1968" TOTAL_1="9" TOTAL_2="9" WEIGHT="28.015935853088553"/>
<CONT_DATA CI_END="-0.1089939187315479" CI_START="-0.9657475249191607" EFFECT_SIZE="-0.5373707218253543" ESTIMABLE="YES" MEAN_1="2.56" MEAN_2="3.01" ORDER="139606" SD_1="0.83" SD_2="0.83" SE="0.21856360957282273" STUDY_ID="STD-Lee-1973b" TOTAL_1="45" TOTAL_2="42" WEIGHT="38.01068718767388"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.9667937682316938" CI_END="0.6444040846744826" CI_START="-0.01948957091926784" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.3124572568776074" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="0.8092861533907862" P_Q="1.0" P_Z="0.06505372264228752" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="71" TOTAL_2="71" UNITS="" WEIGHT="99.99999999999999" Z="1.8448887559878513">
<NAME>Grip strength</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.9667937682316938" CI_END="0.6444040846744826" CI_START="-0.01948957091926784" DF="3.0" EFFECT_SIZE="0.3124572568776074" ESTIMABLE="YES" I2="0.0" ID="CMP-002.03.01" NO="1" P_CHI2="0.8092861533907862" P_Z="0.06505372264228752" STUDIES="4" TAU2="0.0" TOTAL_1="71" TOTAL_2="71" WEIGHT="99.99999999999999" Z="1.8448887559878513">
<NAME>Allocation concealment unclear</NAME>
<CONT_DATA CI_END="1.0237014962700357" CI_START="-0.12339107510912684" EFFECT_SIZE="0.4501552105804544" ESTIMABLE="YES" MEAN_1="213.0" MEAN_2="157.0" ORDER="139607" SD_1="136.0" SD_2="107.0" SE="0.2926310331279764" STUDY_ID="STD-Dick-1970" TOTAL_1="24" TOTAL_2="24" WEIGHT="33.496551803045946"/>
<CONT_DATA CI_END="1.6137606758814187" CI_START="-0.40472092361739453" EFFECT_SIZE="0.6045198761320121" ESTIMABLE="YES" MEAN_1="356.0" MEAN_2="271.0" ORDER="139608" SD_1="151.0" SD_2="112.0" SE="0.5149282373095472" STUDY_ID="STD-Jasani-1968" TOTAL_1="8" TOTAL_2="8" WEIGHT="10.81801171282383"/>
<CONT_DATA CI_END="0.824648307827726" CI_START="-0.3890196458885826" EFFECT_SIZE="0.2178143309695717" ESTIMABLE="YES" MEAN_1="109.0" MEAN_2="99.0" ORDER="139609" SD_1="47.0" SD_2="43.0" SE="0.3096148611121343" STUDY_ID="STD-Lee-1973a" TOTAL_1="21" TOTAL_2="21" WEIGHT="29.92245808173634"/>
<CONT_DATA CI_END="0.7746985213206625" CI_START="-0.533279612380914" EFFECT_SIZE="0.12070945446987423" ESTIMABLE="YES" MEAN_1="73.1" MEAN_2="68.0" ORDER="139610" SD_1="43.5" SD_2="39.0" SE="0.33367402258886925" STUDY_ID="STD-Lee-1974" TOTAL_1="18" TOTAL_2="18" WEIGHT="25.762978402393877"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>